Neoadjuvant chemotherapy:The touchstone of targeted therapy of HER-2 positive breast cancer / 中国癌症杂志
China Oncology
;
(12): 584-589, 2013.
Article
in Chinese
| WPRIM
| ID: wpr-438457
ABSTRACT
The overexpression of human epidermal growth factor receptor 2 (HER-2) is generally considered as an signiifcant predictor of poor prognosis, but the outcome has been rewritten with the appearance and application of the HER-2 targeted monoclonal antibody trastuzumab and chemotherapy plus targeted therapy. For the superiority of acting as in vivo susceptibility” test, neoadjuvant chemotherapy has become a new comprehensive treatment mode for operable breast cancer. And it has also provided an important approach to investigate the effectiveness of newly appeared targeted therapy. We focused more on reviewing and analyzing the results of clinical trials related to preoperation chemotherapy and the latest studies in HER-2 positive breast cancer in this article.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Prognostic study
Language:
Chinese
Journal:
China Oncology
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS